Cytarabine: all 556 studies that test it
Page 4 of 6. Open to participants first (82), then studies with results posted, then the rest; newest registration first within each.
- Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDSCompletedNCT03459859Phase 1
- Epacadostat, Idarubicin and Cytarabine (EIC) in AMLWithdrawnNCT03444649Phase 1
- Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1
- A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AMLStatus unknownNCT03417427Phase 2
- RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCTStatus unknownNCT03412266Phase 2
- Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 MutationsStatus unknownNCT03381781Phase 2
- DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast ExcessStatus unknownNCT03356080Phase 2
- Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03330821Phase 1/2
- A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaWithdrawnNCT03324243Phase 2
- Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic LeukemiaStatus unknownNCT03318419Phase 2
- ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016Active, not recruitingNCT03286634Phase 2
- A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years OldStatus unknownNCT03257241Phase 3
- Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT03181815Phase 2
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid TumorsCompletedNCT03082144Phase 2
- Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AMLActive, not recruitingNCT03021330Phase 3
- The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell LymphomaStatus unknownNCT03016988Phase 2
- Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT02985372Phase 3
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT02957032Phase 1
- Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLCompletedNCT02937662Phase 2
- A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute LeukemiaCompletedNCT02930109Phase 1/2
- Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AMLCompletedNCT02891278Phase 1
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedNCT02881086Phase 3
- Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AMLTerminatedNCT02875093Phase 1
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- Optimal Treatment Strategy Based on for Pediatric AMLStatus unknownNCT02848183Phase 2
- LBL-2016 for Children or Adolescents in ChinaActive, not recruitingNCT02845882Phase 3
- Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell LymphomaCompletedNCT02840539Phase 2
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
- Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic MalignanciesWithdrawnNCT02718755Phase 2
- Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT02676323Phase 1
- Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALLStatus unknownNCT02660762Phase 2
- LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02652871Phase 1
- Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02635074Phase 1
- Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in RemissionWithdrawnNCT02587871Phase 2
- Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02573363Phase 1
- Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT02570542Phase 2
- A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaWithdrawnNCT02532192Phase 1
- 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaWithdrawnNCT02472626Phase 1/2
- Ponatinib for FLT3-ITD Acute Myelogenous LeukemiaCompletedNCT02428543Phase 1/2
- Epigenetic Reprogramming in Relapse AMLTerminatedNCT02412475Phase 1
- A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AMLCompletedNCT02403310Phase 1
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid LeukaemiaStatus unknownNCT02277847Phase 4
- Azacytidine Plus FLAG for Relapsed or Refractory AMLStatus unknownNCT02275663Phase 2
- Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02243436Phase 1/2
- Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic SyndromeCompletedNCT02212561Phase 1
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisActive, not recruitingNCT02205762Phase 2/3
- Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AMLTerminatedNCT02109627Phase 1
- Study of Molecular and Genetic Abnormalities in Patients With Myeloid NeoplasmsCompletedNCT02084563Phase 2
- Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid LeukemiaStatus unknownNCT02072811Phase 3
- Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02070458Phase 1
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
- Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic LymphomaTerminatedNCT02043587Phase 2
- Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaCompletedNCT02036489Phase 4
- Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
- Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger PatientsCompletedNCT01999413Phase 2
- A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic LeukemiaActive, not recruitingNCT01920737Phase 2
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 1
- High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaActive, not recruitingNCT01840566Phase 1
- Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 1
- Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01822015Early Phase 1
- Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid LeukemiaTerminatedNCT01801046Phase 1
- Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01787474Phase 1
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous LeukemiaCompletedNCT01773408Phase 1
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01768897Phase 1
- Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)CompletedNCT01723657Phase 2
- Risk-adapted Therapy for Adult Acute Myeloid Leukemia.CompletedNCT01716793Phase 2
- Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01701323Phase 1
- Lenalidomide Plus Chemotherapy for AMLCompletedNCT01681537Phase 1
- Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast CancerCompletedNCT01645839Phase 3
- A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01641250Phase 1
- Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeTerminatedNCT01636609Phase 1
- A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01635296Phase 1
- Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML ConsolidationStatus unknownNCT01615757Phase 3
- Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in ChildrenStatus unknownNCT01593488Phase 2
- 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid LeukemiaStatus unknownNCT01587430Phase 4
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT01567059Phase 2
- A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the BrainTerminatedNCT01563614Phase 1
- Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01555268Phase 1
- Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AMLStatus unknownNCT01534702Phase 1/2
- Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsCompletedNCT01516580Phase 3
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60aCompletedNCT01497002Phase 3
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnNCT01478074Phase 1
- Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01463046Phase 1
- Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
- ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDSStatus unknownNCT01423175Phase 2
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60aStatus unknownNCT01414231Phase 3
- Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaTerminatedNCT01408160Phase 1
- CHemoImmunotherapy With Early Central Nervous System (CNS) ProphylaxisCompletedNCT01325194Phase 2
- Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic SyndromesWithdrawnNCT01302106Phase 2
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01249430Phase 1